Skip to main content
NAMS
NASDAQ Life Sciences

CHMP Backs Obicetrapib, Paving Way for EU Approval in 2H26

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$31.35
Mkt Cap
$3.571B
52W Low
$21.135
52W High
$42.205
52W Position info
48% above low
Off High info
26% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NAMS sits 48% above its 52-week low of $21.135.

Summary

The CHMP positive opinion is a major regulatory win for obicetrapib, recommending EU marketing authorization for both the monotherapy and fixed-dose combination. This follows the 8-K filed today and builds on positive Phase 3 data from BROADWAY, BROOKLYN, and TANDEM. The European Commission decision is expected in the second half of 2026, and approval would unlock a large European market where Menarini holds commercialization rights. NewAmsterdam stands to receive tiered double-digit royalties and up to €833 million in milestones. With the PREVAIL cardiovascular outcomes trial fully enrolled, this de-risks the regulatory path and strengthens the commercial outlook.

At the time of this announcement, NAMS was trading at $31.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $21.14 to $42.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

NAMS - Latest Insights

NAMS
Nov 04, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $18.32 info
Change: -$2.37 (-11%) info
Market Cap: $2.208B info
NAMS
Nov 04, 2026, 7:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.24
Real-time Price: $18.32 info
Change: -$1.92 (-9%) info
Market Cap: $2.208B info
NAMS
Sep 29, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.71
Real-time Price: $18.32 info
Change: -$5.39 (-23%) info
Market Cap: $2.208B info
NAMS
Sep 22, 2026, 4:58 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.32
Real-time Price: $18.32 info
Change: -$5.00 (-21%) info
Market Cap: $2.208B info
NAMS
Sep 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $22.82
Real-time Price: $18.32 info
Change: -$4.50 (-20%) info
Market Cap: $2.208B info